Xeris Biopharma (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy Sells 16,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the sale, the director owned 126,500 shares in the company, valued at approximately $770,385. This represents a 11.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of XERS stock opened at $6.18 on Friday. The firm has a market cap of $1.07 billion, a P/E ratio of 103.00 and a beta of 0.78. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $10.08. The business’s 50 day moving average price is $6.10 and its 200-day moving average price is $6.59. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. On average, equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on XERS. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $10.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in XERS. UBS Group AG increased its position in Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after purchasing an additional 1,554,869 shares during the period. Vanguard Group Inc. increased its position in Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd grew its position in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after buying an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. Finally, Granahan Investment Management LLC grew its position in shares of Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after buying an additional 873,236 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.